[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vasovagal-syncope\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vasovagal-syncope":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,75,107,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100320017","assessment-of-stroke-volume-and-cardiac-output-in-response-to-varying-heart-rates-100320017",false,"NCT03446326","Assessment of Stroke Volume and Cardiac Output in Response to Varying Heart Rates","Assessment of Stroke Volume and Cardiac Output in Response to Varying Heart Rates and Body Position - a Pacemaker Based Study","Pacing_SV","Inclusion Criteria:\n\n* Age 18-70 years (inclusive)\n* Implanted permanent pacemaker or implanted defibrillator capable of atrial and ventricular pacing\n* LV ejection fraction \\>50%\n\nExclusion Criteria:\n\n* Unable or unwilling to provide informed consent\n* Clinical need for a cardiac resynchronization device","ALL","18 Years","70 Years",{"count":21,"type":22},25,"ESTIMATED","INTERVENTIONAL",[25],"NA","The investigators will seek to determine the effects of different heart rates on both stroke volume and cardiac output using non-invasive hemodynamic assessments. In order to safely manipulate the HR, the investigators will study patients with permanent pacemakers in whom heart rate manipulation can be done in a safe and non-invasive manner.",[28],"Vasovagal Syncope",[30,31,32,33],"pacemaker","stroke volume","cardiac output","heart rate","RECRUITING","2026-04-30",{"date":37,"type":38},"2026-05-05","ACTUAL",{"date":40,"type":38},"2018-01-01",{"date":42,"type":22},"2028-01-01",{"name":44,"class":45},"University of Calgary","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100487006","the-effect-of-water-carbonation-on-orthostatic-tolerance-100487006","NCT05621460","The Effect of Water Carbonation on Orthostatic Tolerance","Inclusion Criteria:\n\n* healthy, English-speaking\n\nExclusion Criteria:\n\n* pregnancy or suspected pregnancy, history of cardiovascular disease, history of neurological disease, history of recurrent fainting (≥ 2 episodes of fainting with loss of consciousness in the prior 6 months)",true,"19 Years","50 Years",{"count":21,"type":22},[25],"The primary purpose of this investigation is to determine whether water carbonation can improve orthostatic tolerance in healthy control volunteers. Orthostatic tolerance refers to the ability to maintain an adequate blood pressure when standing. In some individuals blood pressure can fall when standing, predisposing to dizzy spells or fainting episodes. Drinking water can boost blood pressure and making fainting episodes less likely. However, it is not clear whether the carbonation of the water has any further impact on the blood pressure response. This is important because it may be that carbonated water expands the stomach (gastric distension), provoking an increase in sympathetic activity. The increase in sympathetic nervous system activity boosts blood pressure. Resolving this question would have important implications for patients with syncope. This study will test whether carbonated water will have any further impact on blood pressure than the already known effect of non-carbonated water.",[60,61,28],"Orthostatic Hypotension","Syncope",[63,64,65],"Tilt table","Osmopressor reflex","Gastropressor reflex","2026-04-22",{"date":68,"type":38},"2026-04-23",{"date":70,"type":38},"2023-09-01",{"date":72,"type":22},"2027-04",{"name":74,"class":45},"Simon Fraser University",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":86,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":46},"100528861","cardioneuroablation-for-recurrent-vasovagal-syncope-and-bradyarrhythmias-the-cna-fwrd-registry-100528861","NCT06166277","Cardioneuroablation for Recurrent Vasovagal Syncope and Bradyarrhythmias: The CNA-FWRD Registry","Cardioneuroablation for the Management of Patients With Recurrent Vasovagal Syncope and Symptomatic Bradyarrhythmias: The CNA-FWRD Registry","CNA-FWRD","Inclusion Criteria:\n\n* symptomatic vasovagal syncope or symptomatic bradyarrhythmia refractory to behavioral and medical measures\n* age \\\u003C 60 years\n\nExclusion Criteria:\n\n* age \\> 60 years\n* intra-\u002Finfra-Hisian AV block\n* intrinsic sinus node disease\n* history of supraventricular tachycardia\n* history of ventricular tachycardia\n* presence of structural heart disease related\n* prior history of catheter ablation\n* presence of inheritable arrhythmic conditions\n* orthostatic hypotension on HUTT test\n* abnormal thyroid function levels\n* Proven indication for permanent pacemaker implantation","60 Years",{"count":85,"type":22},300,"3 Years","OBSERVATIONAL","The CNA-FWRD Registry is an international prospective observational multicenter registry of patients with symptomatic vasovagal syncope and bradyarrhythmias managed under routine care by medical therapy and radiofrequency catheter ablation of ganglionated plexi or permanent pacemaker implantation.",[28,90,91],"AV Block-2Nd Degree-Type 1","Sinus Pause",[93,94,95,30,96,97],"vasovagal syncope","av block","sinus pause","cardioneuroablation","radiofrequency ablation","2025-09-17",{"date":100,"type":38},"2025-09-18",{"date":102,"type":38},"2024-08-01",{"date":104,"type":22},"2027-04-30",{"name":106,"class":45},"Rush University Medical Center",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":117,"conditions":118,"keywords":122,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":46},"100541588","clinical-association-between-obstructive-sleep-apnea-facial-pigmentation-and-vasovagal-symptoms-100541588","NCT06331819","Clinical Association Between Obstructive Sleep Apnea, Facial Pigmentation, and Vasovagal Symptoms.","Clinical Association Between Obstructive Sleep Apnea (OSA) and Facial Pigmentation, and the Relation Between OSA and Vasovagal Symptoms With Resulting Smoking Tendency and the Effect of Treatment in Patients Referred for Sleep Study.","VasOSA","Inclusion Criteria:\n\n* Patients within age limit who agree to participate and sign the consent form.\n\nExclusion Criteria:\n\n* Patients with prior diagnosis of obstructive sleep apnea by sleep study.",{"count":116,"type":22},200,"The goal of this prospective cohort study is to study patients referred for sleep study by in-lab polysomnography in the Jordan University Hospital and the Jordan Hospital or with an at-home sleep study kit. The main aims are:\n\n* To prospectively obtain demographic and clinical information of patients referred for a sleep study.\n* To determine the diagnostic value of facial discoloration as potential marker for obstructive sleep apnea to increase detection rate for the condition.\n* To establish a correlation between obstructive sleep apnea and vasovagal symptoms with resulting increased smoking tendency and study the effect of treatment on the disorders.\n* To determine the association between timing of appearance of obstructive sleep apnea symptoms and initiation of smoking.",[119,28,120,121],"Obstructive Sleep Apnea","Smoking","Acanthosis Nigricans",[119,28,123,121,124,125,126],"Facial Discoloration","Smoking Cessation","Jordan","In-Lab Polysomnography","2024-09-07",{"date":129,"type":38},"2024-09-19",{"date":131,"type":38},"2024-03-10",{"date":133,"type":22},"2026-03-01",{"name":135,"class":45},"Jordan Collaborating Cardiology Group",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":46},"100451529","phase-3-study-of-atomoxetine-in-the-prevention-of-vasovagal-syncope-100451529","NCT05159687","Study of Atomoxetine in the Prevention of Vasovagal Syncope","A Randomized, Prospective, Placebo-Controlled, Crossover Study of Atomoxetine in the Prevention of Vasovagal Syncope (POST7)","POST7","Inclusion Criteria:\n\n1. Syncope according to the American College of Cardiology Guidelines 2017\n2. At least 2 vasovagal syncope spells in the preceding 12 months\n3. At least -2 on the Syncope Symptom Score for Structurally Normal Hearts\n4. At least 18 years old with informed consent\n\nExclusion Criteria:\n\n1. Other cause of syncope\n2. A 5-minute stand test resulting in the diagnosis Orthostatic Hypotension or Postural Orthostatic Tachycardia Syndrome\n3. An inability to give informed consent\n4. Pregnant\n5. Unwilling or unable to use adequate birth control while on study drug.\n6. An important valvular, coronary, myocardial, or conduction abnormality, or significant arrhythmia\n7. Uncontrolled hypertension\n8. Uncontrolled hyperthyroidism\n9. A permanent pacemaker\n10. Taking or has recently taken a monoamine oxidase inhibitor\n11. Pheochromocytoma\n12. Glaucoma\n13. Prior use of atomoxetine for syncope\n14. Clinical need for atomoxetine or another potent norepinephrine transporter inhibitors (Ki NET \\\u003C Ki SERT, Ki NET \\> 10 Ki atomoxetine),\n15. Current use of β-blocker, bupropion, α1-adrenergic agonists or antagonists, tricyclic antidepressants, serotonin reuptake inhibitors, scopolamine, theophylline, or fludrocortisone.",{"count":145,"type":22},180,[147],"PHASE3","Project rationale: Vasovagal syncope (VVS) affects up to 50% of people, and recurrent syncope markedly reduces quality of life. We recently reported that it is frequently associated with injury and not surprisingly with clinical anxiety. Although conservative measures help many patients there remain many who require more care. CIHR-funded studies have shown that fludrocortisone and midodrine are effective but cannot be used in patients with contraindications such as hypertension and heart failure. Pacemakers are partially effective in older patients, but this is established only in the small minority with proven asystole. There remains a need for a simple, once-daily medication with few contraindications that can be used as first-line therapy for most patients with recurrent vasovagal syncope.\n\nPreliminary Studies: Norepinephrine transport (NET) inhibitors show promise as a novel treatment. Three (reboxetine, sibutramine, and atomoxetine) all prevent vasovagal syncope in healthy subjects and vasovagal syncope patients on tilt tests. Atomoxetine, approved to treat attention deficit disorder, is a highly selective NET inhibitor. We reported a proof-of-principle, randomized, placebo-controlled trial of the efficacy of atomoxetine to prevent vasovagal syncope on tilt table tests. Patients underwent tilt testing after receiving either atomoxetine 40 mg or placebo. Fewer VVS patients fainted with atomoxetine than placebo (10\u002F29 vs. 19\u002F27; odds ratio 0.22, p \\\u003C 0.01). Our meta-analysis of the effects of NET inhibition on the vasovagal reflex induced by tilt tests was highly positive. A pre-post study showed that sibutramine reduced syncope frequency in highly symptomatic and drug-refractory patients. A similar pre-post study showed that atomoxetine also reduces syncope frequency about 85% in patients with frequent and drug-intolerant or drug-resistant vasovagal syncope. Therefore,NET inhibition by atomoxetine merits assessment based on positive proof-of-principle studies, an apparent class effect, and two open-label pre-post studies. These results provide the rationale for a formal randomized, placebo-controlled, crossover trial of atomoxetine in moderate-to-high risk patients with VVS.\n\nHypothesis: We will test the hypothesis that oral atomoxetine prevents syncope in patients with recurrent VVS.\n\nThe Study: Patients will be included based on a positive Calgary Syncope Symptom Score and a history of at least 2 faints in the previous year. Eligible patients will be randomized to atomoxetine 40 mg po twice daily or matching placebo in a randomized, placebo-controlled, parallel design, double-blind, crossover trial. Each arm will last 6 months with a 1-week washout period. The primary outcome measure will be the proportion of patients with at least 1 syncope recurrence. The study will be powered to detect a beneficial odds ratio of 0.5, selected on the basis of the control outcome rates in 2 similarly designed, previous studies and international expert requirements for effect size. A sample size of 180 subjects will provide 85% power of detecting a difference between the arms at p\\\u003C0.05. We will assess the effects of atomoxetine on quality of life, anxiety, injury, and the cost-effectiveness of atomoxetine treatment, and the effects of genetic factors on outcomes.\n\nSubstudies : The quality of life scales will be the SF-36 and the Euroqol EQ5D, which will also be used as the health utility index for the economic studies. The depression and anxiety scales will be the Hospital and Anxiety Depression Score (HADS) and the General Anxiety Disorder - 7 Score (GAD-7). Clinical anxiety is highly prevalent in patients with recurrent syncope. Injury will be self-reported using our published definitions. The health economic substudy will be from the health system perspective and will use Alberta administrative data. DNA will be collected from spit acquired in the Oragene saliva self-collection kits, and an initial candidate gene study might include alleles of CYP2D6, COMT, the serotonin (SLC6A4) and norepinephrine (SLC6A2) reuptake transporters, and the 5HT1A and 5HT3 receptors.\n\nSummary: Adults who faint recurrently are highly symptomatic. There are no therapies suitable for most patients have withstood the test of randomized clinical trials. If successful, atomoxetine will reduce syncope and improve quality of life.",[28],[151,93,152,153,154],"reflex fainting","randomized clinical trial","quality of life","Atomoxetine","2024-05-08",{"date":157,"type":38},"2024-05-09",{"date":159,"type":38},"2022-06-01",{"date":161,"type":22},"2027-09",{"name":44,"class":45}]